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Abstract
Background: A key goal of anemia management in dialysis patients is to maintain patients’ hemoglobin (Hb)
levels consistently within a target range. Our aim in this study was to assess the association of facility-level practice
patterns representing Hb measurement and erythropoiesis-stimulating agent (ESA) dose adjustment frequencies
with facility-level Hb variation.
Methods: This was a retrospective observational database analysis of patients in dialysis facilities affiliated with large
dialysis organizations as of July 01, 2006, covering a follow-up period from July 01, 2006 to June 30, 2009. A total of
2,763 facilities representing 436,442 unique patients were included. The predictors evaluated were facility-level Hb
measurement and ESA dose adjustment frequencies, and the outcome measured was facility-level Hb variation.
Results: First to 99th percentile ranges for facility-level Hb measurement and ESA dose adjustment frequencies
were approximately once per month to once per week and approximately once per 3 months to once per
3 weeks, respectively. Facility-level Hb measurement and ESA dose adjustment frequencies were inversely
associated with Hb variation. Modeling results suggested that a more frequent Hb measurement (once per week
rather than once per month) was associated with approximately 7% to 9% and 6% to 8% gains in the proportion
of patients with Hb levels within a ±1 and ±2 g/dL range around the mean, respectively. Similarly, more frequent
ESA dose adjustment (once per 2 weeks rather than once per 3 months) was associated with approximately 6%
to 9% and 5% to 7% gains in the proportion of patients in these respective Hb ranges.
Conclusions: Frequent Hb measurements and timely ESA dose adjustments in dialysis patients are associated with
lower facility-level Hb variation and an increase in proportion of patients within ±1 and ±2 g/dL ranges around the
facility-level Hb mean.
Background
A central aim of anemia management in dialysis patients
is to maintain patients’ hemoglobin (Hb) levels consis-
tently within a target range. Anemia management guide-
lines and protocols thus require appropriate adjustment
of erythropoiesis-stimulating agent (ESA) doses in
response to Hb deviations relative to the target range.
There are varied opinions among clinicians, however,
regarding practice patterns that help achieve this objec-
tive [1-7].
The current US Food and Drug Administration-
approved ESA label recommends an Hb target range of 10
to 12 g/dL when treating dialysis patients [8,9], which
represents a slightly broader range than the 11 to 12 g/dL
Hb target currently recommended by the National Kidney
Foundation [10]. Recent data from randomized clinical
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concerns regarding deleterious effects observed with Hb
targets of 13-15 g/dL in patients with chronic kidney
disease who are treated with ESAs [11-14]. At the
same time, however, there are adverse consequences
associated with low Hb levels [15-21]. Thus, at the
level of individual dialysis provider, Hb target ranges
have been influenced by the need to balance these
opposing risks with the benefits of achieving Hb levels
within the 10 to 12 g/dL range.
Recently, the Centers for Medicare and Medicaid Ser-
vices proposed a rule for the End-Stage Renal Disease
Prospective Payment System that includes a payment
penalty for dialysis facilities that maintain more than a
specified proportion of patients in Hb <10 or >12 g/dL
ranges [22]. It is therefore helpful for clinicians to
understand the nature of anemia management protocols
that could maximize the number of patients within the
desired Hb target range. Our aim in this study was to
use the historical cross-sectional and longitudinal varia-
tion in the facility-level practice patterns of Hb mea-
surement and ESA dose adjustment frequencies to study
their association with the facility-level Hb variation,
which is a key summary measure of a facility’sa b i l i t yt o
maintain patients within a given Hb target range.
Methods
A retrospective observational database was constructed
from electronic patient-level data contributed by large
dialysis organizations (LDOs) in the United States. An
LDO was defined as a chain of >500 affiliated dialysis
centers. All data were de-identified in accordance with
the Health Insurance Portability and Accountability Act
Privacy Rule for limited use datasets; thus no additional
institutional review board approval was sought for this
study. This database has been described in detail in a
previous publication [23]. Data from July 2006 to June
2009 (36 months) were extract e df r o md i a l y s i sc e n t e r s
affiliated with an LDO as of July 01, 2006. A study time
period of July 2006 to June 2009 was chosen because it
coincided with a significant longitudinal variation in the
facility-level Hb variation, Hb measurement frequency,
and ESA dose adjustment frequency. This longitudinal
variation was influenced in part by regulatory and reim-
bursement changes for ESAs during this time. Only
hemodialysis (HD) patients with >30 days of data during
this 36-month interval were selected. Included HD
patients represented only the thrice-weekly in-center
HD modality, while other variants of HD treatment
(daily, home, nocturnal, etc.) were not included in the
cohort. Although ESA administration was not consid-
ered an inclusion/exclusion criterion, the ESA type vari-
able in the analysis dataset and available LDO protocol
information indicated that all ESA administrations in
the final study cohort were in the form of intravenous
epoetin alfa.
The dialysis facility was regarded as the unit of analy-
sis. For each dialysis facility, the following sets of
variables were calculated for each month during the
study. They were (1) Hb variation, defined as the SD of
all Hb measurements across all patients; (2) the number
of patient-days, defined as the summation across all
patients of the following measure: date of last patient-
level dialysis session - date of first patient-level dialysis
session + (7/3), with 7/3 applied to adjust for the fol-
low-up truncation at the last observation in a month,
assuming the average sequence of dialysis sessions was
3 times per week (TIW) for HD patients; (3) Hb
measurement frequency, defined as the number of Hb
measurements across all patients divided by the number of
patient-days/30; and (4) ESA dose adjustment frequency,
defined as the number of ESA dose adjustments across all
patients divided by the number of patient-days/30.
Only persistent dose changes were regarded as true
clinical dose adjustments (i.e., those that appeared as
a-a-a-b-b-b, as opposed to a-a-a-b-a-a, over a TIW
sequence). Dose changes were considered to be persis-
tent if they lasted for at least 3 TIW sessions for non-
zero doses and at least 9 TIW sessions for zero doses.
The longer time requirement for zero-dose adjustments
helped reduce potential misclassification of intentional
clinical adjustments to zero doses with hospitalization
events. We validated the methodology with data from
patients for whom hospitalization information was avail-
able (approximately 50% of the study cohort). The vali-
dation step indicated that this methodology would result
in a very low proportion (approximately 0.3%) of dose
adjustments that could be potentially misclassified. We
believe that this level of error is unlikely to cause a
meaningful impact on the results. The algorithm
adopted for identifying dose changes considered the
entire patient-level longitudinal data before further cate-
gorization by calendar months. The calendar month
boundaries thus did not interfere with the definition of
a dose change.
We summarized the aggregate variation in facility-level
Hb variation, Hb measurement frequency, and ESA dose
adjustment frequency by pooling these measurements
across all facility-month combinations and calculating
basic descriptive statistics. A continuous distribution
curve for these measures was created by calculating the
percentage of facility-months within specific intervals. By
adopting a method similar to one in a previous publica-
tion [23], we produced a smooth approximation of the
distribution curve to avoid unnecessary attention to den-
sity fluctuations in low-prevalence buckets. The longitu-
dinal variation in these measures was summarized by
calculating the mean (95% CI) values by each month
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introduced as a weight in these calculations.
We studied associations between facility-level Hb var-
iation and Hb measurement frequency and between
facility-level Hb variation and ESA dose adjustment fre-
quency by using a mixed-modeling regression approach
that partitioned cross-sectional and longitudinal infor-
mation in the data [24-26]. This modeling framework
was adopted to address the unavailability of facility-level
characteristics, which was one of the main limitations of
the analysis dataset. When conclusions regarding asso-
ciations in this modeling framework are drawn from the
longitudinal part of the model, the same facility will
effectively act as its own control over time, and the
primary source of bias will be limited to systematic
longitudinal changes in aggregate facility-level character-
istics. The technical details and underlying rationale
behind this are discussed more fully in previous work
using these models [24-26].
We considered 2 separate models for studying the
associations between facility-level Hb variation and Hb
measurement frequency and between facility-level Hb
variation and ESA dose adjustment frequency due to the
relatively high collinearity between Hb measurement
and ESA dose adjustment frequencies. An additional
reason for considering 2 separate models was that a
model which simultaneously considered both these fac-
tors could introduce a conceptual possibility that the
benefit from these factors in terms of their implications
on Hb variation could be regarded as additive and can
accrue independently. Though the benefit from Hb mea-
surement frequency can be considered to accrue inde-
pendently, the same cannot be said about the ESA dose
adjustment frequency since any practical anemia man-
agement protocol would consider Hb measurement fre-
quency to exceed the ESA dose adjustment frequency.
The fixed- and random-effects part of these mixed mod-
els included an identical set of parameters representing
an intercept term, a linear cross-sectional slope para-
meter, and a linear longitudinal slope parameter. The
number of patient-days was introduced as a weight in
the preceding models. The mixed models were imple-
mented using Proc MIXED in SAS (SAS Institute Inc.,
Cary, NC, USA). All analyses were performed in SAS,
version 9.1.3.
We consider the model relating facility-level Hb varia-
tion and Hb measurement frequency as not being influ-
enced by an endogeneity problem due to omission of
the number of Hb measurements from the model. This
is because we defined Hb variation in terms of SD. The
expectation of Hb variation is therefore independent of
sampling more or less Hb observations, which would
influence the precision of estimating the SD. We would
highlight that we have not defined Hb variation as the
precision of SD, but SD itself, which is a summary mea-
sure of the width of the facility-level Hb distribution
curve.
Please see the Technical Appendix (Additional file 1)
for further information regarding model formulation.
Results
A total of 2,763 facilities were included in the analysis.
They represented all LDO-affiliated facilities as of July
01, 2006, and accounted for approximately 60% of all
dialysis facilities in the United States at that time. Data
from 2,734 facilities (99% of the original cohort) were
available for all 36 months of follow-up, with the
remaining facilities (1%) lost to follow-up owing to clo-
sure. The total number of unique patients and facility-
month combinations represented in the analysis dataset
during the 36-month study period were 436,442 and
98,717, respectively.
Figure 1A summarizes the distribution of facility-level
Hb variation across facility-months. The mean facility-
level Hb variation was 1.34 g/dL, with 1st and 99th per-
centiles ranging from 0.92 to 1.88 g/dL. Under the
assumption of normality for Hb distribution curve at
any point in time (corroborated in previous analyses
considering a large cohort of patients [23,27]), the pro-
portion of patients with Hb within ±1 and ±2 g/dL
around the mean was higher for the 1st percentile beha-
vior as compared with the 99th by approximately 32%
and 26%, respectively (the percentage point difference
represents p99 - p1, where p99 and p1 denote the pro-
portion of patients in specific ranges for facility-months
representing the 99th and 1st percentile behavior,
respectively). The distribution of facility-level Hb varia-
tion was largely symmetrical about the mean with a
slight positive skew (skewness factor, 0.49).
Figures 1B and 1C summarize the distributions of facil-
ity-level Hb measurement and ESA dose adjustment fre-
quencies across facility-months. The mean facility-level
Hb measurement frequency was 2.65 per month (approxi-
mately once per 1.5 weeks), with 1st and 99th percentiles
ranging from 1.10 to 4.65 per month (approximately once
per month to once per week). The distribution of facility-
level Hb measurement frequency was bimodal with peaks
at approximately 1.97 and 3.74 per month (approximately
once per 2 weeks and once per 1 week). The distribution
of facility-level Hb measurement frequency had a positive
skew (skewness factor, 0.70), indicating a small proportion
of facility-months with Hb measurement frequency signifi-
cantly exceeding the mean. The mean of facility-level ESA
dose adjustment frequency was 0.85 per month (approxi-
mately once per 5 weeks) with 1st and 99th percentiles
ranging from 0.31 to 1.50 per month (approximately once
per 3 months to once per 3 weeks). The distribution of
facility-level ESA dose adjustment frequency was largely
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(skewness factor, 0.39). There was a significant positive
correlation between the distributions of facility-level Hb
measurement and ESA dose adjustment frequencies with
an estimated Pearson Correlation Coefficient of 30.7%
(P < 0.001).
Figure 2 summarizes the longitudinal variation in the
mean values of facility-level Hb variation, Hb measure-
ment frequency, and ESA dose adjustment frequency.
Mean facility-level Hb variation (Figure 2A) decreased
from 1.41 g/dL (95% CI, 1.40-1.42 g/dL) in July 2006 to
1.24 g/dL (95% CI, 1.23-1.24 g/dL) in June 2009. Under
the assumption of normality for Hb distribution curve
at any time point, this indicated that on average a facil-
ity’s ability to maintain patients within ±1 and ±2 g/dL
around the mean during the study period increased by
approximately 6% and 5%, respectively. Mean facility-
level Hb measurement frequency (Figure 2B) increased
from 2.50 per month (95% CI, 2.47-2.54 per month) in
July 2006 to 3.12 per month (95% CI, 3.08-3.16 per
month) in June 2009, while mean facility-level ESA dose
adjustment frequency (Figure 2C) increased from 0.76
per month (95% CI, 0.75-0.77 per month) in July 2006
to 1.01 per month (95% CI, 1.00-1.02 per month) in
June 2009.
Table 1 provides a summary of the estimates for fixed-
effect parameters for the previously described models
that evaluated the associations between facility-level Hb
variation and Hb measurement frequency and between
facility-level Hb variation and ESA dose adjustment fre-
quency. For both models, the estimates for intercept,
cross-sectional parameter, and longitudinal parameter
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Figure 2 Trend of the mean values of study variables by month across facilities. (A) Hb variation, (B) Hb measurement frequency, and (C)
ESA dose adjustment frequency. Bands represent 95% CI. ESA = erythropoiesis-stimulating agent; Hb = hemoglobin.
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Page 4 of 8were significant (P < 0.001). The estimates for cross-sec-
tional and longitudinal parameters for both models were
negative, which indicated a consistent negative associa-
tion between facility-level Hb variation and Hb measure-
ment frequency and between facility-level Hb variation
and ESA dose adjustment frequency. The magnitude of
associations as informed by the cross-sectional and
longitudinal parameters was not markedly different for
both of these models. Based on the mean values of Hb
measurement and ESA dose adjustment frequencies, the
difference between cross-sectional and longitudinal
parameter estimates translated to a relatively low facil-
ity-level Hb variation difference of approximately 0.03 g/
dL to 0.05 g/dL as measured by the standard deviation.
Formal testing, however, indicated that the cross-sec-
tional and longitudinal parameters were statistically dif-
ferent from one another with a P-value for the
difference <0.001 for both models.
Figures 3A and 3B provide a graphical summary of the
cross-sectional and longitudinal associations between
facility-level Hb variation and Hb measurement
frequency and between facility-level Hb variation and
ESA dose adjustment frequency. These results indicate
that under the assumption of normality for Hb distribu-
tion curve at any time point, an increase in Hb mea-
surement frequency from once per month to once per
week (from approximately 1st to 99th percentile beha-
vior) was associated with an increase in the proportion
of patients with Hb within the ±1 and ±2 g/dL around
the mean by approximately 9 and 8 percentage points,
respectively, according to the cross-sectional model, and
by approximately 7 and 6 percentage points, respec-
tively, according to the longitudinal model. Similarly, an
increase in ESA dose adjustment frequency from once
per 3 months to once per 3 weeks (from approximately
1st to 99th percentile behavior) was associated with an
increase in the proportion of patients in these ranges by
approximately 5 and 4 percentage points, respectively,
according to the cross-sectional model, and by approxi-
mately 4 and 3 percentage points, respectively, accord-
ing to the longitudinal model. When we modeled an
increase in ESA dose adjustment frequency from once
Table 1 Fixed-effect parameter estimates for mixed models
Fixed-Effect Parameter Estimates* (95% CI)
Model Intercept Cross-Sectional Parameter Longitudinal Parameter
Facility-level Hb variation and Hb measurement frequency 1.558 −0.083 −0.066
(1.543 to 1.573) (−0.089 to −0.078) (−0.070 to −0.062)
Facility-level Hb variation and ESA dose adjustment frequency 1.443 −0.133 −0.096
(1.427 to 1.460) (−0.154 to −0.112) (−0.104 to −0.088)
These estimates assess the associations between facility-level Hb variation and Hb measurement frequency and between facility-level Hb variation and ESA dose
adjustment frequency.
ESA = erythropoiesis-stimulating agent; Hb = hemoglobin.
*All P < 0.001.
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more consistent with the modeled increase in Hb measure-
ment frequency, and the associated increases in the pro-
portion of patients in these ranges were 9 and 7 percentage
points, respectively, according to the cross-sectional model,
and 6 and 5 percentage points, respectively, according to
the longitudinal model.
Discussion
We can suggest plausible mechanisms that may be
responsible for driving the observed variation in facility-
level anemia management practice patterns and their
association with the facility-level Hb variation reported
in this study. The relatively wide variations observed in
facility-level Hb measurement and ESA dose adjustment
frequencies suggest that physicians exercise a significant
level of control over these practice patterns in their indi-
vidual units. Thus, facilities with a higher rate of Hb
monitoring may represent physicians who value an
assessment of both point-in-time Hb measurement as
well as the trend. Assessment of an Hb trend can be
helpful; if the trajectory of Hb levels is suggestive of a sys-
tematic decline despite stable ESA dosing levels (poten-
tially due to unanticipated changes in a patient’s
underlying clinical situation driven by concurrent clinical
factors and a high level of comorbidity burden), protocols
that encourage timely upward adjustment of ESA doses
will be associated with better Hb control. Similarly, if the
reverse situation occurs, ESA dosing protocols that
encourage a timely reduction or temporary discontinua-
tion of ESAs will result in significantly better control in
managing unintended excursions towards the higher Hb
ranges. If ESA doses are temporarily withheld to manage
high Hb level excursions, the practice of frequent Hb
monitoring also allows for a timely re-initiation of treat-
ment before Hb levels decrease too much.
When the range of facility-level Hb variation from
modeled scenarios was compared with the range repre-
sented in the 99th to 1st percentile behavior, it indicated
that practice patterns considered in the current study
represented only 20% to 30% of the potential for redu-
cing the facility-level Hb variation. This is to be
expected because there are a number of other unrelated
factors and practice patterns that could influence the
facility-level Hb variation. For example, one such prac-
tice pattern is the detailed nature of ESA dose adjust-
ments as a function of specific Hb levels. Similarly, iron
administration and iron indices can also influence
response to erythropoietin: intravenous iron supplemen-
tation is independently associated with the risk of
exceeding targeted Hb levels [28] and changes in intra-
venous iron administration have been associated with
hemoglobin cycling [3]. These factors, though critically
important in terms of how they could influence the
facility-level Hb variation, are outside the scope of the
current study.
The bimodal distribution of facility-level Hb measure-
ment frequency reflects the fact that the most popular
protocols concerning Hb measurement frequencies were
either once per week or once per 2 weeks, with once
per 2 weeks being the more prevalent protocol. The
increase in mean facility-level Hb measurement fre-
quency seen in Figure 2B reflects a systematic practice
pattern shift to monitoring Hb levels more frequently, a
behavior that was likely partially driven by changes in
the regulatory and reimbursement environment con-
cerning ESA treatment [23]. The alternating nature of
mean facility-level Hb measurement frequency by
month seen in Figure 2B could be the result of Hb mea-
surement frequency being defined in this analysis at a
monthly level, whereas the Hb measurement protocols
that were actually being adopted by the dialysis facilities
were defined in terms of time intervals counted by
weeks. The increase in mean facility-level ESA dose
adjustment frequency seen in Figure 2C reflected a sys-
tematic practice pattern shift towards adjusting ESA
doses more frequently during the study period, from a
frequency of approximately once per 6 weeks to once
per 4 weeks, a behavior that was likely driven by the
need for maintaining patients’ Hb levels within a nar-
rower target range. The same alternating pattern of
mean facility-level ESA dose adjustment frequency by
month was observed in Figure 2C with an underlying
explanation similar to the trend for mean facility-level
Hb measurement frequency in Figure 2B.
Our method of simultaneously modeling cross-sec-
tional and longitudinal associations in the data is similar
to that described elsewhere [24-26]. Details concerning
the underlying methodology suggest that the same facil-
ity will effectively act as its own control over time in the
part of the model informing longitudinal associations.
Thus, the longitudinal part of the model helps offset the
lack of facility-level covariates, which is one of the main
limitations of our analysis data set. The primary source
of bias in this case will be the systematic changes in
aggregate facility-level characteristics, such as mean
demographics and comorbidities, over time. However,
these aggregate characteristics change over a much
longer time horizon compared with the changes in the
practice patterns considered in this study [29]. The
cross-sectional and longitudinal parameter estimates
were not markedly different from one another, with the
difference translating to a facility-level Hb variation dif-
ference of approximately 0.03 to 0.05 g/dL as measured
by the standard deviation, which could be considered as
a value of low practical significance. This suggests that
even a purely cross-sectional analysis for assessing these
associations may be considered as being somewhat
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moderation in confounding when an individual facility
(as opposed to an individual patient) is regarded as the
unit of analysis has been argued in previous studies that
have used this approach in the context of dialysis
patients [30,31] as well as other settings [32]. However,
this perspective should be considered in light of results
from formal statistical testing which indicated that the
cross-sectional and longitudinal parameters were statisti-
cally different from one another, thus technically sup-
porting the design of the current model simultaneously
considering cross-sectional and longitudinal effects. We
regard the facility-level framework adopted in this analy-
sis, together with the modeling framework that parti-
tioned the cross-sectional and longitudinal variation in
the data, as methodologic advantages that could moder-
ate the burden of confounding factors.
There are a number of important limitations of our
study that warrant careful consideration. It is possible
that the set of studied facility-level practice patterns
did not exert a direct causal impact on Hb variation,
but were surrogates for diligent anemia management
that could have resulted in a simultaneously elevated
likelihood of the implementation of the described
practice patterns as well as a reduction in Hb varia-
tion owing to other unrelated factors. These unrelated
factors, for example, could represent independent
facility-level practice patterns implemented to address
the need for managing Hb levels within a narrower
target range over time. An important limitation of the
analysis dataset was the unavailability of facility-level
demographic characteristics or comorbidity informa-
tion. However, we have provided a summary descrip-
tion of how the adopted modeling framework could
have moderated this limitation. The modeling frame-
work was able to effectively utilize the main strengths
of the database, which included the availability of con-
sistent longitudinal data at a patient-level and the abil-
ity to map patients to individual dialysis facilities.
Other important limitations of the study include the
fact that only HD patients within the LDO segment receiv-
ing intravenous ESA were represented, which limits the
extrapolation of results to other patient and dialysis provi-
der segments. Additionally, patients included in the analy-
sis received only intravenous epoetin alfa and,
consequently, these results should be considered valid
only for this drug and route of administration. In addition,
impact on facility-level Hb variation due to potential
changes in patient-level iron markers and intravenous iron
administration were not captured in the analysis due to
unavailability of this data. We have implicitly assumed
that the longitudinal changes in the Hb distribution curve
at the facility-level during the study time period were
primarily influenced by changes in practice patterns
concerning Hb measurement and ESA dose adjustment
administration frequencies.
Conclusions
This study offers useful hypotheses regarding the nature
of anemia management practice patterns in dialysis
patients that could result in lower facility-level Hb varia-
tion and an increase in the proportion of patients within
±1 and ±2 g/dL ranges around the facility-level Hb
mean. In particular, this study suggests that the practice
patterns of frequent Hb measurements and timely
adjustments of ESA doses could be helpful in attaining
this objective.
Additional material
Additional file 1: Technical Appendix. This appendix contains
additional description regarding the model formulation, covariance
structure, parameter estimation, and confidence intervals. The appendix
also contains residual diagnostics for assessing model adequacy and
results from an unweighted analysis.
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